膜杰作
Star Staining
分子别名（Synonym）
Smstr2,Somatostatin R2,somatostatin receptor 2,somatostatin receptor type 2,SomatostatinR2,SRIF-1,SS2R,SS-2-R,SS2-R,SST2,SSTR2
表达区间及表达系统（Source）
Human SSTR2 Full Length Protein-VLP (SS2-H5216) is expressed from human 293 cells (HEK293). It contains AA Met 1 - Ile 369 (Accession # P30874-1).
Predicted N-terminus: Asp
蛋白结构（Molecular Characterization）
The protein has a calculated MW of 45.3 kDa | 56.1 kDa.
Virus-like particles(VLPs) are formed by self-assembly of envelop/capsid proteins from viruses. Membrane Proteins can be constituted in-situ with VLPs produced from HEK293 cell cultures. These VLPs concentrate conformationally intact membrane proteins directly on the cell surface and produce soluble, high-concentration proteins perfect for immunization and antibody screening.
The VLPs provide the display of properly folded membrane proteins in their native cellular membrane in a compact size of 100~300 nm diameter (similar to the size of most viruses) making it optimal targets for dendritic cells in vivo and surface attachment for phage display.
内毒素（Endotoxin）
Less than 1.0 EU per μg by the LAL method.
制剂（Formulation）
The VLPs are highly immunogenic, so the immunization strategy should be optimized (antigen dose, regimen and adjuvant).
Supplied as 0.2 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
运输（Shipping）
This product is supplied and shipped with dry ice, please inquire the shipping cost.
存储（Storage）
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- The product MUST be stored at -70°C or lower upon receipt;
- -70°C for 12 months under sterile conditions.
活性（Bioactivity）-ELISA
Immobilized Human SSTR2 Full Length Protein-VLP (Cat. No. SS2-H5216) at 5 μg/mL (100 μL/well) can bind Anti-SSTR2 Antibody, Human IgG1 with a linear range of 0.3-5 ng/mL (QC tested).
Protocol
背景（Background）
Somatostatin is a peptide with a potent and broad antisecretory action, which makes it an invaluable drug target for the pharmacological management of pituitary adenomas and neuroendocrine tumors. Somatostatin receptors (SSTR1, 2A and B, 3, 4 and 5) belong to the G protein coupled receptor family and have a wide expression pattern in both normal tissues and solid tumors. Investigating the function of each SSTR in several tumor types has provided a wealth of information about the common but also distinct signaling cascades that suppress tumor cell proliferation, survival and angiogenesis. This provided the rationale for developing multireceptor-targeted somatostatin analogs and combination therapies with signaling-targeted agents such as inhibitors of the mammalian (or mechanistic) target of rapamycin (mTOR). The ability of SSTR to internalize and the development of rabiolabeled somatostatin analogs have improved the diagnosis and treatment of neuroendocrine tumors.
